ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs761 M703 M718 M708 M761 M728 M2.92 BRecherche et développement211 M140 M134 M118 M126 M139 M517 MRésultat d'exploitation-435 M58 M191 M172 M-729 M66 M-300 MTotal des produits hors exploitation3 M5 M-13 M6 M31 M-10 M14 MCharges d'intérêts, nettes des intérêts capitalisés113 M81 M-14 M-10 M113 M-12 M—Résultat hors exploitation, hors charges d'intérêts-114 M-79 M1 M9 M-113 M8 M-95 MRevenus/dépenses exceptionnels4 M3 M07 M31 M-6 M32 MRésultat avant impôts-521 M-3 M133 M121 M-756 M-6 M-508 MPart des actionnaires dans le résultat———————Impôts-33 M-67 M11 M172 M279 M11 M473 MIntérêts ne donnant pas le contrôle / intérêts minoritaires2 M000000Autres produits/charges après impôts-21 M-6 M-14 M-2 M-8 M-13 M-37 MRésultat net avant activités abandonnées-490 M64 M122 M-51 M-1.03 B-17 M-981 MActivités abandonnées-22 M62 M-31 M5 M-93 M2 M-117 MRésultat net-512 M126 M91 M-46 M-1.13 B-15 M-1.1 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-512 M126 M91 M-46 M-1.13 B-15 M-1.1 BBénéfice par action de base (BPA de base)-10.250.18-0.09-2.21-0.03-2.15Bénéfice par action dilué (BPA dilué)-10.250.18-0.09-2.21-0.03-2.15Nombre moyen d'actions de base en circulation510 M512 M513 M514 M513 M515 M—Nombre d'actions en circulation après dilution510 M514 M514 M514 M513 M515 M—EBITDA-967 M61 M227 M180 M-1.61 B52 M-1.16 BEBIT-1.2 B-178 M-30 M-57 M-1.85 B-185 M-2.13 BCoût des ventes1.79 B1.76 B1.82 B1.89 B2.4 B1.81 B7.91 BAutres coûts des ventes———————Amortissements (flux de trésorerie)245 M247 M257 M237 M240 M237 M971 M
Baxter International Inc. Common Stock
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.
Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients.
Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services".
Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology.